• Our Services
    • The Information Commons
    • Shifting the Research Paradigm
    • The Cancer Commons Difference
    • Our Approach
  • About Your Cancer
    • Bladder Cancer
    • Brain Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Diffuse Midline Glioma
    • Esophageal Cancer
    • Kidney Cancer
    • Leukemia
    • Liver Cancer
    • Lung Cancer
    • Lymphoma
    • Melanoma
    • Ovarian Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Uterine Cancer
  • About Us
    • Our Story
    • Facing Advanced Cancer
    • Meet the Team that Cares
    • Distinguished Advisors
    • Our Partners
    • Support Our Services
    • Talk to Us
    • Financial Documents
  • Testimonials
    • All Testimonials
  • Support Us
    • Many Ways to Give
    • What Your Support Makes Possible
  • Our Services
    • The Information Commons
    • Shifting the Research Paradigm
    • The Cancer Commons Difference
    • Our Approach
  • About Your Cancer
    • Bladder Cancer
    • Brain Cancer
    • Breast Cancer
    • Colorectal Cancer
    • Diffuse Midline Glioma
    • Esophageal Cancer
    • Kidney Cancer
    • Leukemia
    • Liver Cancer
    • Lung Cancer
    • Lymphoma
    • Melanoma
    • Ovarian Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Uterine Cancer
  • About Us
    • Our Story
    • Facing Advanced Cancer
    • Meet the Team that Cares
    • Distinguished Advisors
    • Our Partners
    • Support Our Services
    • Talk to Us
    • Financial Documents
  • Testimonials
    • All Testimonials
  • Support Us
    • Many Ways to Give
    • What Your Support Makes Possible
 

Molecular Testing Options

Molecular tests help match patients to the personalized treatments that are most likely to work for them. Keep up with new developments in genetic tests, blood tests, liquid biopsies, tumor mutations, other biomarkers, precision medicine, next-generation sequencing, and more.

  • October 30, 2015  

    To Type or to Print? Oncotype DX and Mamma/BluePrint Tests for Breast Cancer

    Emma Shtivelman, PhD

    Women diagnosed with localized breast cancer face difficult decisions with their doctors. What kind of neoadjuvant (before surgery) treatment to choose? Should chemotherapy follow surgery? Based on the subtype of breast cancer, should specific chemotherapy drugs be used?

  • September 9, 2015  

    To PD-L1 or Not to PD-L1: That Is the Question

    Emma Shtivelman, PhD

    These days, it seems that I write mostly about immune checkpoint blockade drugs, or some other new immunotherapy treatment for cancer. This post is no different—it covers PD-L1, a protein that is at the center of clinical decisions for selecting patients who are likely to benefit from treatment with an anti-PD-1 or anti-PD-L1 drug.

  • August 13, 2015  

    What Determines Whether a Melanoma Patient Will Respond to Checkpoint Blockade Drugs?

    Emma Shtivelman, PhD

    Of all cancer types, melanoma is the most investigated in terms of its potential to be treated through immune system-based approaches. More immunotherapy drugs are approved for melanoma than for any other type of cancer, and more are in development. Recent additions to the immunotherapy arsenal are the ‘anti-PD-1’ immune checkpoint blockade drugs pembrolizumab (Keytruda) and nivolumab (Opdivo).

    • «
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6

The personalized “second opinion” did wonders to reassure that I was on the right path to manage my disease. The process was transparent and remarkably easy. My personal thanks to Lola for the constant feedback and communication.

Dave
Patient with metastatic neuroendocrine tumor of the pancreas



Precision oncology is very complicated and changes every day. The scientists of Cancer Commons provide rapid, compassionate, scientifically sound information about best options, a remarkable free service.

Razelle Kurzrock, MD
U.C. San Diego, CureMatch, Inc.

Our Mission: Cancer Commons is a non-profit network of patients, scientists, and physicians united by a shared goal—to optimize each patient’s outcome and maximize collective learning to benefit the next patient.

Don’t miss Cancer Commons Connects
Insights and stories—from and for our community

Working.

Our Services

  • Care Navigation
  • Personalized Action Plans
  • Registering with Cancer Commons
  • Frequently Asked Questions (FAQ)

Perspectives

  • Latest Research
  • Treatment Options
  • Molecular Testing
  • Navigating Treatment
  • Living with Cancer
  • Patient Stories
  • Curious Dr. George
  • The Big Picture

Organization

  • Our Story
  • Our Team
  • Our Core Values
  • Board of Directors
  • Partners
  • Expert Physician Advisors
  • Careers

About Us

  • News and Events
  • Financial Documents
  • Contact Us

Support & Giving

  • Contribute Now
  • Many Ways to Give
  • What Your Support Makes Possible
  • Testimonials


Donate

Cancer Commons
2625 Middlefield Road Suite 104
Palo Alto, CA 94306

650-289-4044

Patient Hotline

877-971-1200

  • Privacy Policy

© 2025 Cancer Commons.